

I. Remarks

This amendment is being submitted in response to the Examiner's telephone call on September 14, 2006. Applicants thank the Examiner for his comments and suggestions to further the prosecution of the application.

After entry of the amendment, claims 6-8 and 10-25 are pending.

In the specification and claims 6, 10, 18, 21 and 22, the word "compound" has been deleted from "compound SPM 5186" and "compound SPM 5185".

In the specification and claims 6, 10, 18 and 25 the name of the compound SPM 6373 has been added.

In the specification and claim 24 the name of the compound SPM 3672 has been added.

In the specification "SP/W 5185, SP/W 5186, SP/M 6373 and SP/W 3672" have been replaced by the name of each compound.

Claims 6, 10 and 18 have been amended to delete the phrase "or a pharmaceutically acceptable salt thereof" following the name of each compound listed in the claim and only included once at the end of each claim.

Claim 24 has been amended to delete the phrase "for decreasing the recurrence of an ulcer."

No issues of new matter should arise and entry of the amendment is respectfully requested.

II. Conclusion

An early and favorable reconsideration and allowance of the pending claims is respectfully requested. The Examiner is encouraged to contact the undersigned to expedited prosecution of this application.

Respectfully submitted,



Belinda M. Lew, Ph.D.
Registration No. 53,212

Date: September 20, 2006
WILMER HALE LLP
1875 Pennsylvania Avenue, NW
Washington, DC 20006
Phone: (202) 663-6029